Global Latent TB Diagnostics Research Report 2023-2027: New Technologies, New Niche Markets, New Market Dynamics Explored

News provided by

Feb 27, 2024, 06:00 ET

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- The "Latent TB Diagnostics Global Markets by Assay, by Risk Factor, and by Lab/Place. With Executive and Consultant Guides and Market Analysis and Forecasts 2023 - 2027" report has been added to ResearchAndMarkets.com's offering.

Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.

TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition? The report forecasts the market size in five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.

The research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Make investment decisions and valuations with confidence using the latest data.

Latent TB Global Diagnostic Markets Overview

Latent TB Diagnostics - Global Market Overview by Country
Global Latent TB Diagnostics Markets Overview by Assay
Global Latent TB Diagnostics Markets Overview by Risk Factor
Global Latent TB Diagnostics Markets Overview by Lab.

By Assay

Latent TB Diagnostic - TST
Latent TB Diagnostic - IGRA
Latent TB Diagnostic -Other

By Risk Factor

Latent TB Diagnostic - HIV
Latent TB Diagnostic - Pediatric
Latent TB Diagnostic - Immigration
Latent TB Diagnostic - Other Risk Factor

By Lab/Place

Latent TB Diagnostic - Hospital Lab
Latent TB Diagnostic - Outpatient Lab
Latent TB Diagnostic - Point of Care
Latent TB Diagnostic - Other Place

Key Topics Covered:

1 Market Guides
1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition
2.1 An Overview of TB Diagnostics
2.1.1 The New Antigen-Based TBST
2.2 Market Definition
2.3 Methodology
2.4 Healthcare and the IVD Industry
2.4.1 Global Healthcare Spending
2.4.2 Spending on Diagnostics
2.4.3 Important Role of Insurance for Diagnostics

3 Tuberculosis - Current Science
3.1 What is Tuberculosis?
3.1.1 Causes
3.1.2 Pathogenesis
3.1.3 Prevention
3.1.4 Treatment
3.2 Diagnosis
3.2.1 Active TB
3.2.2 Latent TB
3.3 Prevalence
3.3.1 Impact of COVID on TB Prevalence

4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Pharmaceutical/Reagent Supplier
4.1.4 Independent Testing Lab
4.1.5 Public National/regional lab
4.1.6 Hospital lab
4.1.7 Physician Lab
4.1.8 Audit Body
4.1.9 Certification Body

5 Market Trends
5.1 Factors Driving Growth
5.1.1 Increasing Prevalence
5.1.2 Increasing Diagnostic Options
5.1.3 The Aging World
5.1.4 Increased Health Care Spending
5.2 Factors Limiting Growth
5.2.1 The Cost Curve Shrinks the Market
5.2.2 The Diagnostics Dillemma
5.2.3 Adoption Lag and Cost Control
5.3 Diagnostic Technology Development
5.3.1 The Multiplex Opportunity
5.3.2 Shifting Role of Physicians in Diagnosis
5.3.3 Diagnostics Moves Out of the Lab
5.3.4 Rapid Testing Changing Medical Practice
5.3.5 The Next Five Years

6 TB Diagnostics - Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
6.3 PerkinElmer Hopes to Gain Market Share against Qiagen
6.4 PBD Biotech to Develop TB Blood Test
6.5 WHO Expands Assessment for TB MDx Developers
6.6 Cepheid Omni POC System Falls Off Radar
6.7 Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
6.8 NGeneBio Gets CE Mark for NGS-Based TB Assay
6.9 MDx TB Assay From PBD Biotech Shows Promise
6.10 Minute Molecular Dx to Launch Rapid PCR Test
6.11 Qiagen Next-Gen TB Test Gains Chinese Approval
6.12 FIND Invests $21M to Launch POC MDx Platforms
6.13 Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
6.14 Oxford Immunotec to Automate Latent TB Test
6.15 LumiraDx Eyes Test Menu Expansion
6.16 BioMerieux Targeting Hospitals With Desktop Latent TB Test

7 Profiles of Key Companies
7.1 AID GmbH
7.2 Beijing Wantai
7.3 bioMerieux Diagnostics
7.4 Boditech Med, Inc
7.5 Endo International
7.6 Erythra
7.7 Generium
7.8 Glory Biotechnologies Corp
7.9 Lionex Diagnostics & Therapeutics GmbH
7.10 Oxford Immunotec (Perkin Elmer)
7.11 Perkin Elmer
7.12 Qiagen
7.13 R-Biopharm AG
7.14 Sanofi
7.15 SD Biosensor
7.16 Serum Institute of India
7.17 Statens Serum Institut
7.18 Zhifei Longcom

For more information about this report visit https://www.researchandmarkets.com/r/hlqhlm

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets